S&P Futures
5,884.50 -11.75 (-0.20%) Dow Futures
43,111.00 -66.00 (-0.15%) Nasdaq Futures
20,464.50 -55.00 (-0.27%) Russell 2000 Futures
2,248.70 -6.80 (-0.30%) Crude Oil
70.43 -0.13 (-0.18%) Gold
2,748.90 +10.00 (+0.37%)
Skye Bioscience, Inc. (SKYE)
After hours:
| Previous Close | 4.6300 |
| Open | 4.8000 |
| Bid | 4.2100 x 200 |
| Ask | 4.2900 x 100 |
| Day's Range | 4.5000 - 5.4800 |
| 52 Week Range | 1.4400 - 19.4100 |
| Volume | |
| Avg. Volume | 324,728 |
| Market Cap | 142.893M |
| Beta (5Y Monthly) | 1.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.6000 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.00 |
GlobeNewswireSkye Bioscience to Participate in Upcoming November Healthcare Investment Conferences
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences: Guggenheim Healthcare Conference (Boston) Presentation, Monday, November 11, 1:00 pm ET + 1x1 meetings UBS Healthcare Conference (Rancho Palos Verdes) Fireside chat, Wednesday, November 13, 12:30
- GlobeNewswire
Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule approach SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on developing new therapeutics for metabolic health, is providing a statement regarding a recent announcement by Novo Nordisk on Phase 2a top-line data wi
